Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John B. Mumm | M | - |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | 5 ans |
Peter Buzy | M | 64 |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | - |
John Conner | M | - |
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 3 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Pavel Khrimian
- Réseau Personnel